(Alliance News) - GlaxoSmithKline PLC and Sanofi PLC on Wednesday announced positive test results for their Covid-19 vaccine candidate which showed that a booster jab delivered "consistently strong immune responses".
Neutralising antibodies increased in the 9- to 43-fold range, London-based GSK and Paris-based Sanofi said, regardless of which initial jab the person took, be it from AstraZeneca PLC, Johnson & Johnson, Moderna Inc, or Pfizer Inc.
"The booster was well tolerated, with a safety profile similar to currently approved Covid-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination," GSK added.
The companies plan to file the booster data with regulators following full phase III results.
"These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received," said Thomas Triomphe, executive vice president of Sanofi Pasteur.
"This is consistent with our efforts to provide relevant responses to evolving public health needs. While pursuing a phase III trial is a challenge in a quickly shifting pandemic environment, we look forward to seeing the results to support submissions of our booster vaccine as quickly as possible."
Roger Connor, president of GSK Vaccines, said: "As the pandemic threat continues with the current dominant Delta variant and Omicron rapidly gaining ground, booster vaccines will continue to be needed to help protect people over time. The initial booster data are promising, and we await the Phase 3 results to determine the next steps on making protein-based adjuvanted Covid-19 vaccines available."
Glaxo shares were down 0.4% to 1,591.40 pence each in London on Wednesday morning, while Sanofi was marginally higher at EUR85.51 each in Paris.
By Greg Roxburgh; gregroxburgh@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
Glaxosmithkline (GSK)
